Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S. states told Reuters.

Liraglutide is sold under the brand names Saxenda and Victoza, and sales are declining as blockbuster GLP-1s Ozempic and Wegovy skyrocket in demand.

New clinical-trial data provide powerful evidence that GLP-1 drugs widely taken for weight loss may also help protect against dementia.

A study finds smokers with diabetes on Ozempic have fewer smoking-related medical interactions and interventions compared to those on other diabetes drugs. Research suggests potential for semaglutide in smoking cessation.

Novo Nordisk A/S’s diabetes drug Victoza yielded mixed results in a mid-stage study of Alzheimer’s disease, failing to meet its primary goal while showing hints that larger trials of similar drugs may be successful.

Data from a small clinical trial published on Tuesday showed that a drug from the GLP-1 receptor agonist class known for weight loss slowed the loss of brain volume in people with mild Alzheimer's disease.